Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae.
Enterobacteriaceae clinical isolates harboring KPC-(178 strains) or CTX-M-encoding (67 strains) genes were collected during surveillance programs in the 2000-2007 period; and susceptibility was tested by broth microdilution methods. Organisms were dominantly collected in U.S. hospitals (93%). CTX-M-15 and -14 were the most prevalent CTX-M types (97%), all collected from the United States. KPC producers were isolated in the United States (160/178), Israel, China, and Argentina. bla(CTX-M)-carrying isolates were 95.5 and 98.5%, susceptible to Imipenem and meropenem respectively, and were all susceptible to tigecycline, whereas KPC-producing isolates were highly resistant to all antimicrobials tested except polymyxin B and tigecycline (90.6% and 99.4% susceptibility, respectively). The occurrence of KPC-producing and CTX-M-producing isolates has rapidly increased especially in U.S. hospitals, and expanded therapeutic options are needed to treat infections caused by these emerging organisms.
Castanheira
Mariana
M
JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA. mariana.castanheira@jmilabs.com
Sader
Helio S
HS
Jones
Ronald N
RN
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D001118:Argentina; D002681:China; D024901:Drug Resistance, Multiple, Bacterial; D004755:Enterobacteriaceae / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D004756:Enterobacteriaceae Infections / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology*; D005798:Genes, Bacterial; D006761:Hospitals; D006801:Humans; D015378:Imipenem / Q000494:pharmacology / Q000627:therapeutic use; D007557:Israel; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D011112:Polymyxin B / Q000494:pharmacology / Q000627:therapeutic use; D013845:Thienamycins / Q000494:pharmacology / Q000627:therapeutic use; D000078304:Tigecycline; D014481:United States; D001618:beta-Lactamases / Q000096:biosynthesis* / Q000235:genetics
D000900:Anti-Bacterial Agents; D013845:Thienamycins; D000078304:Tigecycline; D015378:Imipenem; D001618:beta-Lactamases; D000077731:Meropenem; D008911:Minocycline; D011112:Polymyxin B